Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 1/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.60 |
| ▸ | TSHR | P16473 | 3/20 | 0.60 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.60 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6257699 | 1.00 | AHCY (0.62) | AHCYADORA2ATSHRADORA2BADORA3 | |
| SCHEMBL6266706 | 0.97 | AHCY (0.65) | AHCYADORA2ATSHRADORA2BADORA3 | |
| SCHEMBL6259026 | 0.97 | AHCY (0.65) | AHCYADORA2ATSHRADORA2BADORA3 | |
| SCHEMBL5507638 | 0.93 | ADORA2A (0.67) | AHCYADORA2ATSHRADORA2BADORA3 | |
| SCHEMBL5992981 | 0.93 | ADORA2A (0.67) | AHCYADORA2ATSHRADORA2BADORA3 | |
| SCHEMBL5507634 | 0.93 | ADORA2A (0.67) | AHCYADORA2ATSHRADORA2BADORA3 | |
| SCHEMBL5504529 | 0.93 | ADORA2A (0.70) | ADORA2ATSHRADORA2BADORA3ADORA1 | |
| SCHEMBL5510434 | 0.92 | ADORA2A (0.70) | ADORA2ATSHRADORA2BADORA3ADORA1 | |
| SCHEMBL6257614 | 0.91 | ADORA2A (0.69) | AHCYADORA2ATSHRADORA2BADORA3 | |
| SCHEMBL6262038 | 0.89 | ADORA3 (0.59) | AHCYADORA2ATSHRADORA2BADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370568-B1 | CHEMICAL COMPOUNDS | GLAXO GROUP LTD (GB) | 2005-10-12 | — | — | EP | claimed |
| US-20040162422-A1 | adenosine derivatives having an acetylene group in the 4' position, which are adenosine A1 agonists; treating ischaemic heart disease, peripheral vascular disease or stroke or patient suffering pain, a CNS disorder, sleep apnoea or emesis | HALL ADRIAN (GB) | 2004-08-19 | — | — | US | claimed |
| EP-1370568-A1 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2003-12-17 | — | — | EP | claimed |
| WO-2002074780-A1 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2002-09-26 | — | — | WO | claimed |
| EP-1370568-B1 | CHEMICAL COMPOUNDS | GLAXO GROUP LTD (GB) | 2005-10-12 | — | — | EP | disclosed |
| US-20040162422-A1 | adenosine derivatives having an acetylene group in the 4' position, which are adenosine A1 agonists; treating ischaemic heart disease, peripheral vascular disease or stroke or patient suffering pain, a CNS disorder, sleep apnoea or emesis | HALL ADRIAN (GB) | 2004-08-19 | — | — | US | disclosed |
| EP-1370568-A1 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002074780-A1 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162422-A1 | adenosine derivatives having an acetylene group in the 4' position, which are adenosine A1 agonists; treating ischaemic heart disease, peripheral vascular disease or stroke or patient suffering pain, a CNS disorder, sleep apnoea or emesis | ADORA1, ADORA2A, ADORA2B | AHCY 1070/4885ADORA2A 2/4885TSHR 2490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.